Skip to main content
SHINPOONG PHARMACEUTICAL CO.,LTD logo

SHINPOONG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 019170 ISIN · KR7019170000 KO Manufacturing
Open in API
Filings indexed 229 across all filing types
Latest filing 2026-03-30 Board/Management Inform…
Country KR South Korea
Listing KO 019170

About SHINPOONG PHARMACEUTICAL CO.,LTD

https://www.shinpoong.co.kr/en/main/mai…

SHINPOONG PHARMACEUTICAL CO.,LTD. is a research and development-oriented pharmaceutical company that manufactures and markets a wide range of pharmaceutical products and active pharmaceutical ingredients (APIs). The company's portfolio includes finished products such as cephalosporin and penicillin antibiotics, antivirals, anticancer drugs, and painkillers. It also develops and supplies medical devices, including Medicurtain, an anti-adhesion barrier. The company manages the entire production process from raw materials to finished goods, serving both domestic and international markets.

Recent filings

Filing Released Lang Actions
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 1% confidence The document is a Korean regulatory submission titled “사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고,” which translates to “Notification concerning the appointment, dismissal or mid‐term retirement of outside directors.” It is addressed to the Financial Supervisory Service and Korea Exchange and details changes in the board’s composition (outside director appointments). This clearly falls under the category of Board/Management Information (announcement of changes in the company’s board of directors).
2026-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a Korean notice titled “정기주주총회결과” which translates to “Regular Shareholders’ Meeting Results.” It details the approval of financial statements, dividend items, director appointments, agenda items, and voting outcomes with percentages for each resolution. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-03-30 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report' (감사보고서) for Shin Poong Pharmaceutical Co., Ltd. It includes the independent auditor's report (삼일회계법인), financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes (주석). It covers the fiscal year ending December 31, 2025. Since it is a comprehensive audit report containing financial statements and auditor's opinion, it falls under the 'Audit Report / Information' category. FY 2025
2026-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by Shinpoong Pharmaceutical. It contains the auditor's opinion, key financial data (assets, liabilities, equity, profit/loss), and confirmation of the audit completion by Samil PwC. While it provides financial data, it is a regulatory filing announcing the submission of the audit report to the exchange, rather than the full 10-K annual report itself. Therefore, it is classified as an Audit Report/Information document. FY 2025
2026-03-19 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Shin Poong Pharmaceutical Co., Ltd. It contains the agenda for the upcoming Annual General Meeting (AGM), including financial statement approval, board appointments, and governance changes. It also includes detailed management information, board activity reports, and financial statements (balance sheets, income statements) as part of the proxy materials provided to shareholders. This document is a standard Proxy Solicitation & Information Statement (PSI) used to inform shareholders of meeting details and solicit votes.
2026-03-10 Korean
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변경
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from Shin Poong Pharm regarding a correction to a previously announced 'Change in Sales or Profit/Loss Structure of 30% or more'. It provides updated financial figures due to adjustments made during the external audit process. As this is an official regulatory announcement of financial results and subsequent corrections, it falls under the category of general regulatory filings.
2026-03-10 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.